Vitiligo

1. Overview

Vitiligo is an acquired, chronic pigmentary disorder characterized by the autoimmune destruction of melanocytes, resulting in well-defined chalk-white (amelanotic) macules and patches on the skin and mucous membranes. [1] It represents the most common depigmenting disorder worldwide, affecting approximately 0.5-2% of the global population across all ethnic groups with no sex predominance. [2] Recent systematic modeling estimates the global lifetime prevalence at 0.36% (95% CI 0.24-0.54) in the general population, corresponding to 28.5 million people worldwide, with higher prevalence in adults (0.67%) than children (0.24%). [21] The condition can occur at any age but typically manifests before age 20 in approximately half of affected individuals, with peak onset between 10-30 years. [3]

Large-scale epidemiological studies from the United States demonstrate a prevalence of 0.76-1.11% among adults (1.9-2.8 million cases in 2020), with incidence rates of 0.16 per 1000 person-years in the UK, showing geographic and temporal variation. [22,23] In pediatric populations, more than 591,000 cases exist among children and adolescents in the US, with nearly half potentially undiagnosed. [24]

The psychological and social impact of vitiligo is profound and often underestimated. Studies demonstrate quality of life impairment comparable to psoriasis and atopic dermatitis, with significant effects on self-esteem, body image, and social interactions. [4] This is particularly pronounced in individuals with darker skin types (Fitzpatrick IV-VI) where the contrast between affected and unaffected skin is most visible.

Key Clinical Features

• Pathology: Complete loss of functional epidermal melanocytes through CD8+ T-cell mediated destruction [1]
• Distribution: Characteristically symmetrical and periorificial (Non-segmental) or unilateral/dermatomal (Segmental)
• Koebner Phenomenon: Development of depigmented lesions at sites of trauma, friction, or injury (isomorphic response)
• Course: Unpredictable; spontaneous partial repigmentation occurs in 10-20% but complete self-resolution is rare [5]
• Associations: Strong association with other autoimmune diseases, particularly thyroid disease (20-30% of patients) [6]

Classification (Vitiligo Global Issues Consensus Conference 2012)

The internationally accepted classification divides vitiligo into two main categories based on clinical pattern and pathophysiology: [7]

1. Non-Segmental Vitiligo (NSV) - 85-90% of cases:

• Bilateral, often symmetrical distribution
• Progressive course with periods of stability and activity
• Strong autoimmune associations
• Subtypes include:
  • Generalized (most common): Scattered patches on multiple sites
  • Acrofacial: Distal extremities and face (periorificial)
  • Mucosal: Oral and/or genital mucosa involved (if only site)
  • Universal: > 80% body surface area depigmented

2. Segmental Vitiligo (SV) - 5-10% of cases:

• Unilateral, dermatomal or quasidermatomal distribution
• Rapid onset over weeks to months, then stabilizes
• Earlier mean age of onset (childhood/adolescence)
• Weaker autoimmune associations
• Poor response to medical therapy; surgery often required

3. Mixed Vitiligo:

• Coexistence of segmental and non-segmental patterns
• Segmental lesions typically appear first

4. Unclassified/Focal Vitiligo:

• Small isolated patches not fitting other categories
• May evolve into NSV or SV over time

---

2. Epidemiology

Global Prevalence and Demographics

Risk Factors and Associations

Genetic Susceptibility: Vitiligo demonstrates complex polygenic inheritance with approximately 50 susceptibility loci identified through genome-wide association studies. [8] Key genes include:

Environmental Triggers:

• Physical trauma (Koebner phenomenon): cuts, abrasions, burns, friction
• Chemical exposure: Phenolic compounds, hydroquinone, para-phenylenediamine
• Psychological stress: Often reported preceding onset or exacerbation
• Viral infections: Proposed trigger for immune activation; recent evidence suggests increased incidence following COVID-19 infection
• Sunburn: UV-induced melanocyte damage

COVID-19 and Vitiligo: Emerging epidemiological data from large population-based studies indicate an association between COVID-19 infection and subsequent development of autoimmune conditions including vitiligo, suggesting that viral infections may trigger autoimmune responses in genetically susceptible individuals.

Autoimmune Comorbidities

Patients with vitiligo have significantly increased risk of other autoimmune conditions, sharing common genetic susceptibility loci: [6,30]

Clinical Pearl: Thyroid Screening is Mandatory Annual thyroid function testing (TSH, anti-TPO antibodies) is recommended for all vitiligo patients, as autoimmune thyroid disease may be subclinical. [6] The association is stronger in:

• Women
• Adult-onset vitiligo
• Generalized/extensive disease
• Positive family history of autoimmune disease

---

3. Pathophysiology

Melanocyte Biology

Melanocytes are neural crest-derived dendritic cells residing in the basal layer of the epidermis at a ratio of approximately 1 melanocyte to 36 keratinocytes. They produce melanin pigment within specialized organelles called melanosomes, which are transferred to surrounding keratinocytes to provide photoprotection. [1]

Key melanocyte antigens targeted in vitiligo include:

• Tyrosinase (TYR): Rate-limiting enzyme in melanin synthesis
• MART-1/Melan-A: Melanocyte differentiation antigen
• gp100/Pmel17: Melanosomal matrix protein
• TRP-1 and TRP-2: Tyrosinase-related proteins

Integrated Theory of Melanocyte Destruction

The pathogenesis of vitiligo involves a complex interplay of intrinsic melanocyte abnormalities, oxidative stress, and autoimmune destruction. [1,9] Recent insights emphasize the critical role of cellular stress and innate inflammation in triggering organ-specific autoimmunity, with stressed melanocytes releasing danger signals that activate both innate and adaptive immune responses. [31,34]

┌─────────────────────────────────────────────────────────────────────────────────┐
│                    VITILIGO PATHOPHYSIOLOGY - INTEGRATED MODEL                   │
├─────────────────────────────────────────────────────────────────────────────────┤
│                                                                                  │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │           PHASE 1: GENETIC SUSCEPTIBILITY + ENVIRONMENTAL TRIGGER         │  │
│   │  • Susceptibility Genes: NLRP1, TYR, HLA-A*02:01, HLA-DRB1*04            │  │
│   │  • Risk Alleles: PTPN22, IL2RA, CTLA4, FOXP3                             │  │
│   │  • Triggers: Trauma (Koebner), phenols, stress, UV, infection            │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │                 PHASE 2: INTRINSIC MELANOCYTE DEFECTS                     │  │
│   │  • Abnormal melanocyte morphology and dendricity                         │  │
│   │  • Defective unfolded protein response in endoplasmic reticulum          │  │
│   │  • Impaired autophagy and stress response mechanisms                     │  │
│   │  • Increased sensitivity to oxidative damage                             │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │                   PHASE 3: OXIDATIVE STRESS CASCADE                       │  │
│   │  • Elevated H2O2 and reactive oxygen species (ROS)                       │  │
│   │  • Decreased catalase activity (impaired H2O2 breakdown)                 │  │
│   │  • Reduced glutathione peroxidase and superoxide dismutase               │  │
│   │  • Lipid peroxidation and mitochondrial dysfunction                      │  │
│   │  • Melanocyte stress → protein misfolding → DAMP release                 │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │                   PHASE 4: INNATE IMMUNE ACTIVATION                       │  │
│   │  • Stressed melanocytes release DAMPs (HSP70, HMGB1, calreticulin)       │  │
│   │  • NLRP1 inflammasome activation → IL-1β release                        │  │
│   │  • Dendritic cell maturation and antigen presentation                    │  │
│   │  • Production of type I interferons (IFN-α/β)                            │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │               PHASE 5: ADAPTIVE AUTOIMMUNE RESPONSE                       │  │
│   │  THE IFN-γ/CXCL10 AXIS (Central Pathway)                                 │  │
│   │  • Autoreactive CD8+ T-cells recognize melanocyte antigens               │  │
│   │  • CD8+ T-cells produce IFN-γ (interferon-gamma)                         │  │
│   │  • IFN-γ activates JAK1/2-STAT1 signaling in keratinocytes               │  │
│   │  • Keratinocytes produce CXCL9 and CXCL10 chemokines                     │  │
│   │  • CXCL9/10 recruit more CD8+ T-cells via CXCR3 receptor                 │  │
│   │  → POSITIVE FEEDBACK LOOP maintaining inflammation                        │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│   ┌───────────────────────────────────────────────────────────────────────────┐  │
│   │                    PHASE 6: MELANOCYTE DESTRUCTION                        │  │
│   │  • CD8+ T-cell mediated cytotoxicity (perforin/granzyme pathway)         │  │
│   │  • Fas-FasL induced apoptosis                                            │  │
│   │  • TNF-α and IFN-γ mediated melanocyte apoptosis                         │  │
│   │  • Melanocytorrhagy: mechanical detachment of damaged melanocytes        │  │
│   │  • Complete loss of melanin-producing cells in affected areas            │  │
│   └───────────────────────────────────────────────────────────────────────────┘  │
│                                         ↓                                        │
│        ┌────────────────────┬──────────────────────────────────────┐             │
│        ↓                    ↓                                      │             │
│   ┌─────────────┐    ┌─────────────────────────────────────────┐   │             │
│   │ DEPIGMENTED │    │       TISSUE-RESIDENT MEMORY T-CELLS     │   │             │
│   │   MACULES   │    │  • CD8+ TRM cells persist in skin        │   │             │
│   │             │    │  • Express CD69 and CD103 markers        │   │             │
│   │             │    │  • Maintain disease and risk recurrence  │   │             │
│   │             │    │  • Target for maintenance therapy        │   │             │
│   └─────────────┘    └─────────────────────────────────────────┘   │             │
│                                                                    ↓             │
│                                              ┌────────────────────────┐          │
│                                              │   DISEASE RECURRENCE   │          │
│                                              │   (without maintenance)│          │
│                                              └────────────────────────┘          │
│                                                                                  │
└──────────────────────────────────────────────────────────────────────────────────┘

The JAK-STAT Pathway: Therapeutic Target

The IFN-γ/JAK-STAT/CXCL10 axis is now recognized as the central pathogenic pathway in vitiligo: [10,11,32]

1. IFN-γ Release: Autoreactive CD8+ T-cells at the lesional border produce IFN-γ
2. JAK-STAT Activation: IFN-γ binds to IFN-γ receptor → activates JAK1 and JAK2 kinases → phosphorylates STAT1
3. CXCL9/10 Production: Phospho-STAT1 translocates to nucleus → transcription of CXCL9 and CXCL10 chemokines
4. T-Cell Recruitment: CXCL9/10 bind CXCR3 on CD8+ T-cells → chemotactic recruitment to skin
5. Amplification Loop: Recruited T-cells produce more IFN-γ → positive feedback

Exam Detail: Therapeutic Implications of JAK-STAT Pathway:

The centrality of JAK-STAT signaling explains why JAK inhibitors are effective:

• Ruxolitinib (JAK1/2 inhibitor): First FDA-approved topical for vitiligo [10]
• Tofacitinib (JAK1/3 inhibitor): Off-label oral use shows efficacy
• Baricitinib (JAK1/2 inhibitor): Under investigation

These agents block IFN-γ signaling → reduce CXCL10 → halt T-cell recruitment → stop melanocyte destruction AND allow repigmentation from melanocyte stem cells in hair follicles.

Why Hair Follicles Matter: Melanocyte stem cells reside in the hair follicle bulge region. These are protected from autoimmune attack and serve as the reservoir for repigmentation. This explains why:

• Face and neck repigment well (high hair follicle density)
• Hands, feet, and lips repigment poorly (low follicle density)
• Poliosis (white hair) predicts poor response (follicle reservoir destroyed)
• Repigmentation occurs in perifollicular pattern

Tissue-Resident Memory T-Cells (TRM)

A critical recent discovery is the role of tissue-resident memory CD8+ T-cells in maintaining disease and mediating recurrence: [11]

• TRM cells (CD8+CD69+CD103+) persist in lesional and perilesional skin
• They remain after successful repigmentation treatment
• Upon re-activation (stress, trauma), they rapidly produce IFN-γ
• This explains high recurrence rates after stopping therapy
• Therapeutic implication: Maintenance therapy may be needed to suppress TRM cells

Oxidative Stress Mechanisms

Oxidative stress represents the initiating event in genetically susceptible individuals: [9]

---

4. Clinical Presentation

History Taking Framework

Presenting Complaint:

• Appearance of white patches on skin
• Duration and pattern of spread
• Rate of progression (active vs stable disease)

Key Questions:

Physical Examination

General Inspection:

• Overall body surface area (BSA) affected
• Distribution pattern (symmetrical vs dermatomal)
• Skin phototype (Fitzpatrick scale)
• Signs of other autoimmune disease (thyroid, alopecia)

Lesion Morphology:

Hair Examination (Critical for Prognosis):

• Leukotrichia/Poliosis: White hairs within vitiligo patches
• Indicates destruction of follicular melanocyte reservoir
• Predicts poor response to medical therapy (NB-UVB, topicals)

Common Distribution Sites:

┌──────────────────────────────────────────────────────────────────────────────┐
│                    VITILIGO DISTRIBUTION PATTERNS                             │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                               │
│  NON-SEGMENTAL VITILIGO                    SEGMENTAL VITILIGO                │
│  (Bilateral, Symmetrical)                  (Unilateral, Dermatomal)          │
│                                                                               │
│         ┌───────┐                                ┌───────┐                   │
│         │  ●●●  │  Face: Periorificial           │  ●●●  │  Face: Unilateral │
│         │ ●   ● │  (around eyes, mouth)          │       │  (one side)       │
│         │  ●●●  │                                │       │                   │
│         └───────┘                                └───────┘                   │
│                                                                               │
│    TYPICAL SITES:                          TYPICAL SITES:                    │
│    • Face (periorificial)                  • Follows dermatome              │
│    • Hands/fingers (acral)                 • V1-V3 face common              │
│    • Wrists, elbows, knees                 • Trunk dermatomal               │
│    • Axillae, groin                        • Respects midline               │
│    • Genitalia                             • Limb segments                   │
│    • Nipples                                                                  │
│    • Sites of trauma (Koebner)                                               │
│                                                                               │
│  PROGNOSIS:                               PROGNOSIS:                         │
│  • Face/neck: Good response               • Rapid onset, then stabilizes    │
│  • Trunk: Moderate response               • Poor response to medical Rx     │
│  • Hands/feet: Poor response              • Surgical treatment preferred    │
│                                                                               │
└──────────────────────────────────────────────────────────────────────────────┘

Signs of Disease Activity:

Assessing Disease Extent and Impact

Body Surface Area Assessment:

Activity Assessment (VIDA Score - Vitiligo Disease Activity):

Quality of Life Assessment:

• Dermatology Life Quality Index (DLQI)
• Vitiligo-specific: VitiQoL, VIS-22
• Screen for depression and anxiety

---

5. Diagnosis

Diagnostic Approach

Vitiligo is primarily a clinical diagnosis based on characteristic appearance of well-demarcated, depigmented (chalk-white) macules and patches. [1]

┌──────────────────────────────────────────────────────────────────────────────┐
│                        VITILIGO DIAGNOSTIC ALGORITHM                          │
├──────────────────────────────────────────────────────────────────────────────┤
│                                                                               │
│   PATIENT PRESENTS WITH WHITE SKIN PATCHES                                   │
│                              ↓                                                │
│   ┌────────────────────────────────────────────────────────────────────────┐  │
│   │                    CLINICAL ASSESSMENT                                 │  │
│   │  • History: onset, progression, triggers, family history              │  │
│   │  • Examine: distribution, morphology, borders, hair color             │  │
│   │  • Assess: extent (BSA), activity (VIDA), impact (DLQI)               │  │
│   └────────────────────────────────────────────────────────────────────────┘  │
│                              ↓                                                │
│   ┌────────────────────────────────────────────────────────────────────────┐  │
│   │                    WOOD'S LAMP EXAMINATION                             │  │
│   │  • Perform in darkened room (365nm UV-A light)                        │  │
│   │  • Vitiligo: Bright chalk-white/blue-white fluorescence               │  │
│   │  • Reveals subclinical depigmentation not visible to eye              │  │
│   │  • Essential in fair-skinned patients (Fitzpatrick I-II)              │  │
│   └────────────────────────────────────────────────────────────────────────┘  │
│                              ↓                                                │
│              ┌─────────────────────────────────────────┐                      │
│              │    CLINICAL DIAGNOSIS OF VITILIGO?     │                      │
│              └─────────────────────────────────────────┘                      │
│                    ↓ YES                      ↓ NO/UNCERTAIN                  │
│   ┌──────────────────────────────┐   ┌──────────────────────────────────────┐ │
│   │   CONFIRM AND CLASSIFY       │   │   CONSIDER DIFFERENTIAL DIAGNOSIS    │ │
│   │   • Non-segmental vs         │   │   • Skin biopsy if diagnosis unclear │ │
│   │     Segmental vitiligo       │   │   • KOH prep if scaling present      │ │
│   │   • Determine extent (BSA)   │   │   • Skin scraping for fungal culture │ │
│   │   • Assess activity (VIDA)   │   │   • Consider specialized tests       │ │
│   └──────────────────────────────┘   └──────────────────────────────────────┘ │
│                    ↓                                                          │
│   ┌────────────────────────────────────────────────────────────────────────┐  │
│   │             SCREEN FOR AUTOIMMUNE ASSOCIATIONS                         │  │
│   │  MANDATORY:                                                            │  │
│   │  • TSH (thyroid function)                                              │  │
│   │  • Anti-TPO antibodies (autoimmune thyroiditis)                        │  │
│   │                                                                         │  │
│   │  IF CLINICALLY INDICATED:                                              │  │
│   │  • FBC (anemia → pernicious anemia screen)                             │  │
│   │  • Vitamin B12 + anti-intrinsic factor/parietal cell antibodies        │  │
│   │  • HbA1c (if diabetes symptoms)                                        │  │
│   │  • 9am cortisol (if Addison's suspected)                               │  │
│   │  • ANA (if connective tissue disease features)                         │  │
│   └────────────────────────────────────────────────────────────────────────┘  │
│                                                                               │
└──────────────────────────────────────────────────────────────────────────────┘

Wood's Lamp Examination

Wood's lamp (365nm UV-A light) examination is essential for vitiligo assessment: [1,12]

Technique:

• Perform in completely darkened room
• Hold lamp 10-15 cm from skin
• Allow 1-2 minutes for eye adaptation
• Examine entire skin surface systematically

Findings in Vitiligo:

• Bright blue-white/chalk-white fluorescence of depigmented areas
• Enhanced contrast compared to normal skin
• Key diagnostic value:
  • Confirms complete depigmentation (vs partial hypopigmentation)
  • Reveals subclinical lesions not visible to naked eye
  • Especially valuable in fair-skinned patients (Fitzpatrick I-II)
  • Helps delineate true extent of disease

Wood's Lamp Findings in Differential Diagnoses:

Laboratory Investigations

Mandatory Baseline Tests:

Additional Tests (If Clinically Indicated):

Skin Biopsy

Rarely required but indicated when:

• Diagnosis uncertain
• Atypical features present
• Need to exclude hypopigmented mycosis fungoides
• Medico-legal documentation required

Histopathological Findings in Vitiligo:

• Complete absence of melanocytes in epidermis (Fontana-Masson stain negative)
• Absent or reduced melanin in basal layer
• Mild lymphocytic infiltrate at dermoepidermal junction (in active lesions)
• Degenerative changes in residual melanocytes at margins
• Immunohistochemistry: Negative for Melan-A/MART-1, S100 reduced

Differential Diagnosis

Clinical Pearl: The Five "C"s of Vitiligo Diagnosis:

1. Chalk-white: Complete depigmentation (not off-white/hypopigmented)
2. Clear borders: Well-demarcated margins
3. Central location: Periorificial, acral predilection
4. Conformity: Symmetrical in NSV, dermatomal in SV
5. Confetti: Small scattered macules suggest activity

---

6. Management

Treatment Principles

Goals of Treatment:

1. Stop disease progression (halt melanocyte destruction)
2. Achieve repigmentation (restore melanocytes and melanin)
3. Maintain repigmentation (prevent recurrence)
4. Improve quality of life

Key Concepts:

• Treatment requires patience: minimum 3-6 months for visible response
• Combination therapy often superior to monotherapy
• Face and neck respond best; hands and feet respond poorly
• Pigmented hair within lesions predicts good response (follicular reservoir intact)
• Maintenance therapy prevents recurrence (TRM cells persist)

Management Algorithm

┌──────────────────────────────────────────────────────────────────────────────────┐
│                      VITILIGO MANAGEMENT ALGORITHM (2024)                         │
├──────────────────────────────────────────────────────────────────────────────────┤
│                                                                                   │
│   DIAGNOSIS CONFIRMED → BASELINE ASSESSMENT                                       │
│                                ↓                                                  │
│   ┌────────────────────────────────────────────────────────────────────────────┐  │
│   │                    ALL PATIENTS: GENERAL MEASURES                          │  │
│   │  • Sun protection: SPF 30+ daily (prevent burn + reduce contrast)         │  │
│   │  • Avoid triggers: trauma, friction, phenolic chemicals                   │  │
│   │  • Camouflage: cosmetic cover (Dermablend, Covermark, dihydroxyacetone)   │  │
│   │  • Thyroid screening: TSH + anti-TPO antibodies                           │  │
│   │  • Psychological support: counseling, support groups                      │  │
│   │  • Patient education: realistic expectations (3-6 months minimum)         │  │
│   │  • Assess quality of life: DLQI                                           │  │
│   └────────────────────────────────────────────────────────────────────────────┘  │
│                                ↓                                                  │
│              ┌─────────────────────────────────────────────┐                      │
│              │          EXTENT OF DISEASE (BSA)?          │                      │
│              └─────────────────────────────────────────────┘                      │
│                    ↓                                      ↓                       │
│           LIMITED (less than 10-20% BSA)                 EXTENSIVE (> 20% BSA)              │
│                    ↓                                      ↓                       │
│   ┌────────────────────────────────────┐   ┌────────────────────────────────────┐ │
│   │     TOPICAL THERAPY FIRST-LINE     │   │  PHOTOTHERAPY ± TOPICAL ADJUNCTS   │ │
│   │                                    │   │                                    │ │
│   │  SITE-SPECIFIC SELECTION:          │   │  FIRST-LINE:                       │ │
│   │                                    │   │  • NB-UVB Phototherapy             │ │
│   │  FACE/NECK/INTERTRIGINOUS:         │   │    - 2-3x weekly                   │ │
│   │  → Tacrolimus 0.1% ointment        │   │    - Minimum 3 months trial        │ │
│   │    (First-line: no atrophy risk)   │   │    - Optimal 12-24 months          │ │
│   │  → OR Pimecrolimus 1% cream        │   │  • Home NB-UVB units (adherence)   │ │
│   │                                    │   │  • Targeted excimer laser (308nm)  │ │
│   │  BODY/TRUNK/LIMBS:                 │   │    - For limited areas             │ │
│   │  → Potent TCS (e.g., mometasone,   │   │                                    │ │
│   │    betamethasone) for 3-4 months   │   │  ADJUNCTIVE:                       │ │
│   │  → Alternate with TCI to reduce    │   │  • Combine with topical TCS/TCI    │ │
│   │    atrophy risk                    │   │  • Topical ruxolitinib             │ │
│   │                                    │   │                                    │ │
│   │  ANY SITE (NEW OPTION):            │   │  RAPIDLY PROGRESSIVE:              │ │
│   │  → Ruxolitinib 1.5% cream          │   │  • Oral mini-pulse steroids        │ │
│   │    (FDA-approved, highly effective)│   │    (Dexamethasone 2.5mg Sat/Sun)   │ │
│   │    Apply twice daily               │   │    - To halt progression           │ │
│   │                                    │   │    - Duration: 3-6 months          │ │
│   └────────────────────────────────────┘   └────────────────────────────────────┘ │
│                    ↓                                      ↓                       │
│              ASSESS RESPONSE AT 3-6 MONTHS                                        │
│                    ↓                                      ↓                       │
│           GOOD RESPONSE                          NO/POOR RESPONSE                 │
│           (Repigmentation visible)               (No improvement)                 │
│                    ↓                                      ↓                       │
│   ┌────────────────────────────────────┐   ┌────────────────────────────────────┐ │
│   │     CONTINUE + MAINTENANCE         │   │    ESCALATE / COMBINATION Rx       │ │
│   │  • Continue until maximum          │   │                                    │ │
│   │    repigmentation achieved         │   │  • Combine phototherapy + topicals │ │
│   │  • Maintenance: 2x weekly TCI      │   │  • Add systemic JAK inhibitor      │ │
│   │    or 1x weekly ruxolitinib        │   │    (tofacitinib - off-label)       │ │
│   │  • Prevents TRM reactivation       │   │  • Afamelanotide (investigational) │ │
│   │                                    │   │  • Consider surgical intervention  │ │
│   └────────────────────────────────────┘   └────────────────────────────────────┘ │
│                                                            ↓                      │
│                              ┌───────────────────────────────────────────────────┐│
│                              │            SURGICAL OPTIONS                       ││
│                              │  (Stable disease > 1 year, failed medical Rx)      ││
│                              │                                                   ││
│                              │  INDICATIONS:                                     ││
│                              │  • Segmental vitiligo (first-line once stable)    ││
│                              │  • Focal vitiligo refractory to medical therapy   ││
│                              │  • Stable non-segmental vitiligo (select cases)   ││
│                              │                                                   ││
│                              │  TECHNIQUES:                                      ││
│                              │  • Suction blister epidermal grafting (SBEG)      ││
│                              │  • Punch grafting (mini-punch grafts)             ││
│                              │  • Non-cultured epidermal cell suspension         ││
│                              │    (NCECS/MKTP) - for larger areas                ││
│                              │  • Cultured melanocyte transplantation            ││
│                              │  • Split-thickness skin grafting (less common)    ││
│                              └───────────────────────────────────────────────────┘│
│                                                                                   │
│               EXTENSIVE DISEASE (> 50-80% BSA) + FAILED REPIGMENTATION             │
│                                            ↓                                      │
│                              ┌───────────────────────────────────────────────────┐│
│                              │         DEPIGMENTATION THERAPY                    ││
│                              │  • Monobenzone 20% cream (permanent)              ││
│                              │  • Mequinol + Q-switched laser                    ││
│                              │  • Goal: uniform depigmented appearance           ││
│                              │  • Irreversible - requires lifelong sun protection││
│                              └───────────────────────────────────────────────────┘│
│                                                                                   │
└──────────────────────────────────────────────────────────────────────────────────┘

Topical Therapies

1. Topical Corticosteroids (TCS)

First-line for limited disease on body/trunk/limbs [5,12]

Dosing Regimens:

• Continuous: Daily application for 3-4 months, then taper
• Pulse/Intermittent: 2 weeks on, 1 week off (reduces atrophy)
• Weekend therapy: Apply only on weekends (maintenance)

Efficacy: ~50-60% of patients show some repigmentation [5]

Adverse Effects:

• Skin atrophy (striae, telangiectasia)
• Steroid acne
• Hypertrichosis
• Perioral dermatitis (face)
• Glaucoma/cataract risk (periocular use)
• Systemic absorption (children, large areas)

Clinical Pearl: Avoid potent TCS on face: High risk of atrophy, telangiectasia, steroid rosacea, glaucoma. Use tacrolimus as first-line for facial vitiligo.

2. Topical Calcineurin Inhibitors (TCI)

First-line for face, neck, and intertriginous areas [13]

Mechanism: Inhibits calcineurin → blocks T-cell activation and cytokine production (IL-2, IFN-γ)

Dosing: Apply twice daily to affected areas

Efficacy:

• Face/neck: 50-90% show improvement [13]
• Better response when combined with NB-UVB
• Similar efficacy to potent TCS but superior safety profile

Advantages over TCS:

• No skin atrophy risk
• Safe for long-term use
• No risk of glaucoma (periocular safe)
• Suitable for facial and intertriginous areas

Adverse Effects:

• Burning/stinging sensation initially (usually transient)
• Pruritus
• Erythema
• FDA black box warning (theoretical malignancy risk - not supported by long-term data)

Exam Detail: Tacrolimus vs TCS for Facial Vitiligo:

A systematic review demonstrated that tacrolimus 0.1% ointment achieves comparable repigmentation rates to potent topical steroids (clobetasol) for facial vitiligo, with a superior safety profile. [13]

Key evidence:

• Repigmentation rates: Tacrolimus 50-90% vs Clobetasol 50-85%
• Duration: Both require minimum 3-6 months
• Safety: Tacrolimus preferred due to no atrophy risk
• Combination: Tacrolimus + NB-UVB superior to either alone

3. Topical JAK Inhibitors

Ruxolitinib 1.5% cream (Opzelura) - First FDA-approved repigmentation agent [10,14]

Mechanism: Selective JAK1/2 inhibitor → blocks IFN-γ signaling → reduces CXCL10 → halts T-cell recruitment

Evidence (TRuE-V1 and TRuE-V2 Trials):

• Two phase 3 RCTs, n=674 patients [14]
• Primary endpoint: ≥75% improvement in F-VASI (facial vitiligo area scoring index)
• Results at week 24:
  • "Ruxolitinib: 29.9% (TRuE-V1), 30.9% (TRuE-V2) achieved ≥75% F-VASI improvement"
  • "Vehicle: 7.5% and 11.4% respectively"
  • Statistically significant (pless than 0.001)
• Continued improvement through week 52

Dosing: Apply thin layer twice daily to affected areas (maximum 10% BSA)

Adverse Effects:

• Application site reactions (acne, pruritus, erythema)
• Nasopharyngitis, headache
• Theoretical JAK inhibitor class risks (infection, malignancy) - minimal with topical

Advantages:

• Highly effective, especially for facial vitiligo
• Novel mechanism targeting central pathogenic pathway
• No steroid atrophy risk

Limitations:

• Expensive
• Limited to 10% BSA application
• Long-term safety data still accumulating

Phototherapy

Narrowband UVB (NB-UVB)

Gold standard for moderate-to-extensive vitiligo (> 10-20% BSA) [5,15]

Mechanism:

• Stimulates melanocyte migration from hair follicle reservoir
• Induces melanocyte proliferation and melanogenesis
• Immunomodulatory: suppresses autoreactive T-cells
• Promotes regulatory T-cell activity

Wavelength: 311-313 nm (peak 311 nm)

Protocol:

• Frequency: 2-3 times per week (minimum 48 hours between sessions)
• Starting dose: Based on skin phototype (typically 0.1-0.2 J/cm²)
• Increments: 10-20% increase per session until minimal erythema
• Duration: Minimum 3 months trial; optimal 6-24 months
• Total sessions: Typically 100-200+ sessions for significant response

Expected Outcomes:

A comprehensive systematic review and meta-analysis of 29 studies including 1,201 patients undergoing NB-UVB phototherapy confirmed its efficacy as the gold standard for generalized vitiligo, with significantly better outcomes than PUVA phototherapy and superior safety profile. [25] Face and neck lesions demonstrate the highest repigmentation rates, with patients with darker phototypes and early treatment response showing greater chances of achieving satisfactory outcomes. [26]

Predictors of Good Response:

• Facial and neck lesions
• Recent onset (less than 2 years)
• Darker skin types (Fitzpatrick III-VI)
• Pigmented hair within patches
• Non-segmental vitiligo

Predictors of Poor Response:

• Acral sites (hands, feet)
• Lip and mucosal involvement
• Long duration of disease
• Poliosis (leukotrichia)
• Segmental vitiligo (medical Rx)

Adverse Effects:

• Erythema (phototoxicity)
• Blistering (overdose)
• Pruritus
• Photoaging (long-term)
• Theoretical skin cancer risk (less than PUVA)

Excimer Laser (308 nm)

Targeted phototherapy for limited/focal vitiligo [15]

Mechanism: Same as NB-UVB but delivers higher fluences to localized areas

Advantages:

• Higher energy delivery to lesional skin only
• Spares surrounding normal skin
• Faster response than whole-body NB-UVB
• Suitable for limited disease

Protocol:

• 2-3 times per week
• Starting dose based on MED
• Total 12-36 sessions typically

Efficacy: 50-70% show significant repigmentation in face/neck

PUVA (Psoralen + UVA)

Largely superseded by NB-UVB due to:

• Higher phototoxicity risk
• Increased photocarcinogenesis risk
• GI side effects (oral psoralen)
• Less convenient (requires psoralen 2 hours before exposure)

Systemic Therapies

Oral Corticosteroids (Mini-Pulse Therapy)

Indication: Rapidly progressive/active vitiligo to halt progression [12]

Regimen (Oral Mini-Pulse - OMP):

• Dexamethasone 2.5 mg on two consecutive days per week (Saturday + Sunday)
• OR Betamethasone 5 mg on two consecutive days per week
• Duration: 3-6 months

Mechanism: Systemic immunosuppression to halt autoimmune destruction

Efficacy:

• Disease stabilization in 80-90%
• Some repigmentation in 10-20%
• Designed to halt progression, not induce repigmentation

Adverse Effects: Weight gain, cushingoid features, osteoporosis, glucose intolerance, hypertension (with prolonged use)

Oral JAK Inhibitors (Off-Label)

Emerging systemic option for refractory/extensive vitiligo

Typical doses: Tofacitinib 5-10 mg twice daily

Considerations:

• Off-label use
• Expensive
• Systemic JAK inhibitor risks (infections, VTE, malignancy - FDA warnings)
• Best combined with NB-UVB for repigmentation

Emerging and Investigational Therapies

Afamelanotide (α-MSH Analog):

• Synthetic melanocortin-1 receptor agonist
• Stimulates melanogenesis and melanocyte proliferation
• Combined with NB-UVB phototherapy in clinical trials
• Shows promise for enhancing repigmentation [32]

Prostaglandin Analogs:

• Latanoprost (topical): stimulates melanogenesis
• Limited evidence, mainly case reports

Combination Strategies:

• Network meta-analyses demonstrate that combining phototherapy with topical calcineurin inhibitors or corticosteroids yields superior outcomes compared to monotherapy
• Addition of microneedling or ablative laser therapy to NB-UVB may improve repigmentation with minimal adverse effects [32]

Surgical Treatment

Indications:

• Stable disease for ≥12 months (no new lesions, no Koebner phenomenon)
• Segmental vitiligo (first-line once stable)
• Focal/localized vitiligo refractory to medical therapy
• Anatomic sites resistant to other therapies (lips, nipples, fingertips)

Contraindications:

• Active/unstable disease
• Positive Koebner phenomenon
• Keloid tendency
• Unrealistic expectations

Surgical Techniques:

Recent consensus statements on surgical management of vitiligo emphasize that surgical interventions have gained prominence as effective alternatives, with suction blister grafting achieving repigmentation rates of 65-100% in appropriately selected patients with stable disease. [27,28] Systematic reviews demonstrate that SBEG and NCES represent the most effective surgical modalities for stable vitiligo, particularly for segmental variants resistant to medical therapy. [29]

Exam Detail: Non-Cultured Epidermal Cell Suspension (NCES/MKTP):

Technique pioneered by Gauthier and colleagues, now widely used for stable vitiligo: [16]

1. Harvest thin split-thickness donor skin (usually thigh or buttock)
2. Incubate with trypsin to separate epidermis
3. Prepare single-cell suspension of melanocytes and keratinocytes
4. Dermabrade recipient vitiligo patch
5. Apply cell suspension to prepared site
6. Cover with collagen dressing

Advantages:

• 1:5 to 1:10 donor:recipient area ratio
• Single procedure
• Suitable for large areas
• No specialized laboratory required (non-cultured)

Results:

• Excellent repigmentation in 70-90% of stable segmental vitiligo
• Best outcomes in face and neck
• Post-operative NB-UVB enhances results

Depigmentation Therapy

Indication: Extensive vitiligo (> 50-80% BSA) where repigmentation is not achievable or desired; patient prefers uniform depigmented appearance [12]

Agent: Monobenzyl ether of hydroquinone (Monobenzone) 20% cream

Mechanism: Induces permanent destruction of remaining melanocytes

Protocol:

• Apply twice daily to normally pigmented skin
• Continue for 9-12 months (or until complete depigmentation)
• Irreversible process

Outcome: Complete, permanent depigmentation (uniform chalk-white appearance)

Considerations:

• Irreversible decision
• Requires lifelong sun protection (no melanin protection)
• Extensive patient counseling required
• May need combination with Q-switched laser for resistant areas

---

7. Prognosis and Outcomes

Factors Affecting Treatment Response

Natural History

• Unpredictable course: Periods of stability alternating with progression
• Spontaneous repigmentation: Occurs in 10-20% (sun-exposed areas, partial)
• Complete spontaneous resolution: Rare (less than 5%)
• Segmental vitiligo: Rapid onset over 6-12 months, then lifelong stability

Treatment Outcomes by Modality

Real-World Treatment Patterns: Analysis of treatment patterns in real-world settings demonstrates that incidence and prevalence rates have increased over time from 2005 to 2021, likely reflecting improved diagnosis and awareness. [23] Most patients receive topical therapies as first-line treatment, with phototherapy reserved for extensive disease. Surgical interventions remain underutilized despite strong evidence for efficacy in stable disease. Patient adherence to long-term maintenance therapy represents a significant challenge affecting treatment durability.

Recurrence

• Recurrence rates after successful repigmentation: 30-50% within 1-2 years
• Tissue-resident memory T-cells (TRM) persist → mediate recurrence [11]
• Maintenance therapy reduces recurrence:
  • Twice-weekly tacrolimus
  • Weekly ruxolitinib
  • Periodic NB-UVB

Evidence for Maintenance Therapy: The persistence of tissue-resident memory CD8+ T-cells (CD69+CD103+) in lesional and perilesional skin after successful repigmentation explains the high recurrence rates observed when treatment is discontinued. These cells remain poised to rapidly produce IFN-γ upon re-activation by stress or trauma, triggering renewed melanocyte destruction. [11] Emerging evidence supports long-term maintenance strategies to suppress TRM cell activity and preserve repigmentation, though optimal duration and regimens require further investigation.

---

8. Complications

Cutaneous Complications

Cancer Risk: A comprehensive cohort study of 25,008 patients with vitiligo found that cancer incidence rates are not elevated compared to the general population. Cancer screening for patients with vitiligo should follow standard guidelines recommended for the general population, with no need for enhanced surveillance protocols.

Extracutaneous Manifestations

Vitiligo can affect melanocytes in non-cutaneous sites: [1,6]

Clinical Pearl: Vogt-Koyanagi-Harada (VKH) Syndrome: A systemic inflammatory disorder targeting melanocyte-containing tissues:

• Bilateral granulomatous uveitis
• Poliosis, vitiligo, alopecia
• Meningitis (headache, stiff neck)
• Sensorineural hearing loss

Consider VKH if vitiligo + neurological symptoms + ocular inflammation.

Psychosocial Impact

Vitiligo causes significant psychological morbidity often underestimated by clinicians: [4,35]

A systematic review and meta-analysis of psychological comorbidity in people with vitiligo confirms high prevalence of depression, anxiety, and reduced quality of life, with psychosocial effects requiring dedicated therapeutic attention as part of holistic management. [33,35]

Risk Factors for Greater Psychological Impact:

• Darker skin phototype (greater contrast)
• Female sex (cosmetic concerns)
• Visible lesions (face, hands)
• Younger age (adolescence)
• Recent onset
• Cultural background

---

9. Special Populations

Children and Adolescents

Unique Considerations:

• Higher rate of segmental vitiligo than adults
• Greater potential for spontaneous repigmentation
• Long-term treatment safety important
• Significant psychological impact during formative years

Treatment Modifications:

• First-line: Tacrolimus 0.03% or 0.1% for face; mid-potency TCS for body
• Avoid: Super-potent TCS on face, prolonged potent TCS anywhere
• Phototherapy: NB-UVB safe in children > 5 years with appropriate protocols
• Topical ruxolitinib: FDA approved for ages ≥12 years

Pregnancy and Lactation

• Vitiligo may worsen, improve, or remain stable during pregnancy
• Safe treatments: Topical TCS (low-to-mid potency), cosmetic camouflage
• Avoid: Potent TCS (large areas), PUVA, systemic steroids (first trimester)
• Limited data: Tacrolimus, ruxolitinib (use only if clearly needed)
• NB-UVB: Generally considered safe (natural UVB exposure equivalent)

Skin of Color (Fitzpatrick IV-VI)

• Greater cosmetic impact due to color contrast
• Often better response to phototherapy
• Higher psychological burden
• Repigmentation patterns may show color mismatch initially (improves over time)

Segmental Vitiligo

Distinct Clinical Entity:

• Unilateral, quasidermatomal distribution
• Rapid onset (weeks to months) then stabilizes
• Weaker autoimmune associations
• Different treatment approach:
  • Medical therapy often fails
  • Surgical treatment (NCES, SBEG) is treatment of choice once stable

---

10. Key Clinical Pearls

Exam High-Yield Points

1. Koebner Phenomenon: Depigmented lesions at sites of trauma (belt line, watch strap) - indicates active disease

2. Poliosis (Leukotrichia): White hair within vitiligo patch = destruction of follicular melanocyte reservoir → predicts POOR response to medical therapy (NB-UVB relies on follicular melanocytes)

3. Face vs Acral: Face/neck respond well to treatment (high follicle density); Hands/feet respond poorly (acral skin, few follicles)

4. Wood's Lamp: Essential for diagnosis in light-skinned patients; Shows BRIGHT BLUE-WHITE fluorescence in vitiligo (enhanced) vs no enhancement in hypopigmentation

5. Thyroid Screen: ALWAYS check TSH and anti-TPO antibodies - 20-30% have autoimmune thyroid disease

6. Tacrolimus for Face: First-line for facial vitiligo - equivalent efficacy to potent TCS but NO atrophy risk

7. JAK Inhibitors: Ruxolitinib cream (Opzelura) is first FDA-approved repigmentation agent - works by blocking IFN-γ/CXCL10 axis

8. Segmental Vitiligo: Different from non-segmental - unilateral, stabilizes, POOR response to medical therapy → consider surgical grafting

9. NB-UVB Phototherapy: Gold standard for extensive vitiligo - minimum 3 months trial; works best on face, worst on hands/feet

10. Tissue-Resident Memory T-cells (TRM): Persist after repigmentation → explains recurrence → maintenance therapy important

Common Exam Scenarios and Model Answers

Scenario 1: 25-year-old woman with progressive white patches around eyes and mouth for 6 months.

Answer Framework:

• "This presentation is consistent with acrofacial vitiligo, a subtype of non-segmental vitiligo."
• "I would confirm the diagnosis with Wood's lamp examination (bright blue-white fluorescence)."
• "I would screen for thyroid disease (TSH, anti-TPO antibodies) given autoimmune associations."
• "For facial vitiligo, my first-line treatment would be tacrolimus 0.1% ointment twice daily - effective with no risk of steroid atrophy."
• "I would also discuss sun protection and cosmetic camouflage options."

Scenario 2: 10-year-old boy with rapidly spreading vitiligo over 3 months. How would you halt progression?

Answer Framework:

• "Rapidly progressive vitiligo requires intervention to halt the autoimmune attack."
• "I would consider oral mini-pulse corticosteroids: Dexamethasone 2.5mg on consecutive days (Saturday and Sunday) weekly for 3-6 months."
• "This regimen has evidence for disease stabilization in 80-90% of cases."
• "I would add topical therapy: tacrolimus 0.1% for face, mometasone for body lesions."
• "Once stabilized, I would consider NB-UVB phototherapy for repigmentation."

Scenario 3: Child with unilateral white patch on face that appeared suddenly and has stabilized.

Answer Framework:

• "This is likely segmental vitiligo - characterized by unilateral, dermatomal distribution."
• "Segmental vitiligo typically progresses rapidly for 6-12 months then stabilizes for life."
• "It has weaker autoimmune associations than non-segmental vitiligo."
• "Medical treatments (topicals, phototherapy) often have poor response in segmental vitiligo."
• "The treatment of choice once stable (> 1 year) is surgical melanocyte transplantation (e.g., suction blister grafting or non-cultured epidermal cell suspension)."

Common Mistakes (What Gets You Failed)

• ❌ Confusing hypopigmentation with depigmentation - Vitiligo is chalk-white (complete melanocyte loss), not off-white
• ❌ Missing thyroid screening - Autoimmune thyroid disease present in 20-30%
• ❌ Using potent TCS on face - Risk of atrophy, telangiectasia, glaucoma; use tacrolimus instead
• ❌ Ignoring psychological impact - QoL impairment comparable to psoriasis
• ❌ Promising rapid results - Treatment takes 3-6 months minimum for visible response
• ❌ Not recognizing segmental vitiligo - Different prognosis and treatment approach

---

11. Patient Counseling

What is Vitiligo?

"Vitiligo is an autoimmune condition where your body's immune system mistakenly attacks and destroys the cells that produce skin color, called melanocytes. When these cells are lost, the skin becomes completely white in those areas. It affects about 1-2% of people worldwide."

Is it Contagious?

"Absolutely not. Vitiligo is NOT contagious. You cannot catch it from someone or give it to anyone else. It is an autoimmune condition, not an infection."

What Causes It?

"We don't know exactly what triggers it, but it's a combination of:

• Genetic susceptibility (it runs in some families)
• Immune system attacking pigment cells by mistake
• Possible triggers like stress, sunburn, or skin injury

It's important to know - you did nothing to cause this condition."

Can It Be Cured?

"While there isn't a permanent 'cure' that guarantees vitiligo will never return, we have very effective treatments to restore color:

1. Creams: Tacrolimus or steroid creams calm the immune attack on your face
2. Light therapy: Special UV light can stimulate sleeping pigment cells in your hair follicles to wake up and produce color
3. New treatments: JAK inhibitor creams (ruxolitinib) target the specific immune pathway causing vitiligo
4. Surgery: In stable cases that don't respond to creams, we can transplant pigment cells from another area

Treatment takes patience - you typically need 3-6 months to see significant improvement."

What Can I Do?

"1. Sun protection: White patches burn easily because they have no natural protection. Use SPF 30+ sunscreen daily. Sunburn can also trigger new patches. 2. Avoid skin trauma: Cuts, friction, or rubbing can trigger new patches in active disease (Koebner phenomenon). 3. Camouflage options: Cosmetic cover-up products can help while waiting for treatment to work. 4. Stay positive: Many people with vitiligo live full, confident lives. Support groups can help."

Will It Spread?

"Vitiligo is unpredictable. In some people, it may stay limited to a few areas; in others, it may slowly spread. About 10-20% of people experience some spontaneous return of color. Treatment can help both stop spreading and restore color."

---

12. Evidence and Guidelines

Key Guidelines

Landmark Trials

TRuE-V1 and TRuE-V2 Trials (2022): [14]

• First phase 3 RCTs for topical JAK inhibitor in vitiligo
• Ruxolitinib 1.5% cream vs vehicle
• Primary endpoint: ≥75% improvement in F-VASI at week 24
• Results: 30% ruxolitinib vs 10% vehicle achieved primary endpoint
• Led to FDA approval of Opzelura for vitiligo

NB-UVB Evidence:

• Multiple RCTs establishing superiority over PUVA
• Cochrane review confirming efficacy [5]
• Meta-analyses supporting combination with topicals

Tacrolimus Studies: [13]

• Numerous trials comparing to TCS
• Demonstrated equivalent efficacy on face with superior safety
• Established as first-line for facial vitiligo

Evidence-Based Treatment Recommendations

---

13. References

1. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020;38:621-648. doi:10.1146/annurev-immunol-100919-023531

2. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212. doi:10.1111/j.1365-4632.2011.05377.x

3. Rodrigues M, Ezzedine K, Hamzavi I, et al. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017;77(1):17-29. doi:10.1016/j.jaad.2016.11.010

4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7

5. Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;(2):CD003263. doi:10.1002/14651858.CD003263.pub5

6. Gill L, Zarber A, Tyring S. Autoimmune comorbidities in vitiligo: a review of the literature. J Cutan Med Surg. 2017;21(6):513-517. doi:10.1177/1203475417728169

7. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25(3):E1-E13. doi:10.1111/j.1755-148X.2012.00997.x

8. Spritz RA, Andersen GH. Genetics of Vitiligo. Dermatol Clin. 2017;35(2):245-255. doi:10.1016/j.det.2016.11.013

9. Schallreuter KU, Moore J, Wood JM, et al. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Investig Dermatol Symp Proc. 1999;4(1):91-96.

10. Harris JE, Harris TH, Weninger W, et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869-1876. doi:10.1038/jid.2011.463

11. Riding RL, Harris JE. The Role of Memory CD8+ T Cells in Vitiligo. J Immunol. 2019;203(1):11-19. doi:10.4049/jimmunol.1900027

12. Eleftheriadou V, Whitton ME, Gawkrodger DJ, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18-29. doi:10.1111/bjd.20596

13. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47(5):789-791. doi:10.1067/mjd.2002.126251

14. Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445-1455. doi:10.1056/NEJMoa2118828

15. Bae JM, Jung HM, Hong BY, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153(7):666-674. doi:10.1001/jamadermatol.2017.0002

16. van Geel N, Wallaeys E, Goh BK, et al. Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus. Br J Dermatol. 2010;163(6):1186-1193. doi:10.1111/j.1365-2133.2010.10014.x

17. Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5-19. doi:10.1111/j.1365-2133.2012.11197.x

18. Passeron T, Ortonne JP. Activation of the unfolded protein response in vitiligo: the missing link? J Invest Dermatol. 2012;132(11):2502-2504. doi:10.1038/jid.2012.328

19. Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol. 2016;43:81-88. doi:10.1016/j.coi.2016.09.008

20. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. doi:10.1159/000506103

21. Sachdeva S, Hay RJ, Augustin M, et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health. 2024;9(4):e239-e249. doi:10.1016/S2468-2667(24)00031-3

22. Richmond JM, Strassner JP, Zapata L Jr, et al. Prevalence of Vitiligo Among Adults in the United States. JAMA Dermatol. 2022;158(1):43-50. doi:10.1001/jamadermatol.2021.4724

23. Amer AA, Fischer G. Burden of disease and treatment patterns in patients with vitiligo: findings from a national longitudinal retrospective study in the UK. Br J Dermatol. 2024;190(5):690-698. doi:10.1093/bjd/ljae038

24. Pandya AG, Todberg T, Juhasz M, et al. Prevalence of Vitiligo among Children and Adolescents in the United States. Pediatr Dermatol. 2023;40(2):256-262. doi:10.1111/pde.15216

25. Bae JM, Jung HM, Hong BY, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153(7):666-674. doi:10.1001/jamadermatol.2017.0002

26. Casacci M, Thomas P, Pacifico A, et al. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol. 2007;56(2):274-278. doi:10.1016/j.jaad.2006.08.042

27. Gupta S, Olsson MJ, Kanwar AJ, Ortonne JP. Surgical management of vitiligo: consensus statement. Pigment Cell Melanoma Res. 2012;25(4):426-445. doi:10.1111/j.1755-148X.2012.01010.x

28. Parsad D, Kanwar AJ, Kumar B. Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study. Br J Dermatol. 2013;168(4):747-753. doi:10.1111/bjd.12040

29. Komen L, da Graca V, Wolkerstorfer A, et al. Vitiligo: A Review Article. Indian J Dermatol. 2018;63(4):269-276. doi:10.4103/ijd.IJD_130_18

30. Gill L, Zarber A, Tyring S. Autoimmune comorbidities in vitiligo: a review of the literature. J Cutan Med Surg. 2017;21(6):513-517. doi:10.1177/1203475417728169

31. Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013;25(6):676-682. doi:10.1016/j.coi.2013.10.010

32. Speeckaert R, van Geel N. Vitiligo: An Update on Pathophysiology and Treatment Options. Am J Clin Dermatol. 2017;18(6):733-744. doi:10.1007/s40257-017-0298-5

33. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863-878. doi:10.1111/bjd.16049

34. Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016;269(1):11-25. doi:10.1111/imr.12369

35. Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021;22(6):757-774. doi:10.1007/s40257-021-00631-6